MJ
Therapeutic Areas
Janux Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| JANX007 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 |
| JANX008 | Advanced or Metastatic EGFR-expressing Solid Tumors | Phase 1 |
| Undisclosed TRACTr Program | Solid Tumors | Preclinical |
| Undisclosed TRACIr Program | Solid Tumors | Preclinical |
Leadership Team at Janux Therapeutics
DC
David Campbell, Ph.D.
President, Chief Executive Officer, and Director
TR
Tighe Reardon, J.D.
Chief Legal Officer and Corporate Secretary
GG
Gary G. Lyons
Chairman of the Board
JC
John C. Gutheil, M.D.
Director
AK
Aaron Kantoff
Director
KC
Kevin C. Tang
Director
TG
Tommy G. Thompson
Director
WG
Wayne Godfrey
Interim Chief Financial Officer
JA
John A. Josey, Ph.D.
Chief Scientific Officer (likely former)
MK
Mihalis K. Karya, Ph.D.
Senior Vice President, Process Sciences & Manufacturing